Investigation and Evaluation of the Off-label Use of Anlotinib
OBJECTIVE To investigate the off-indication medication of anlotinib in a hospital,and to provide reference for clinical rational application of anlotinib.METHODS To collect the inpatient prescriptions of anlotinib in a hospital from January 2023 to January 2024,and to judge whether the collected prescriptions are off-label accord-ing to the drug instructions of anlotinib.Referring to relevant literature and databases,the prescriptions judged as off-label drug use were classified and statistically analyzed,and evidence-based medical evidence was collect-ed.RESULTS A total of 1702 cases of anlotinib were collected in this survey.By comparing the latest drug instruc-tions,there were 427 cases of off-indication medication,accounting for 25.09％.There were 20 kinds of diseases in-volved,and the most common indications were 116 cases of colorectal cancer,accounting for 27.17％.Among the 427 cases of off-label drug use,the indications supported by strong evidence-based medical evidence included colorectal cancer and ovarian cancer,a total of 164 cases,accounting for 38.40％;the indications supported by weak evidence-based medical evidence were esophageal malignant tumor,hepatocellular carcinoma,biliary tract cancer,etc.,a total of 205 cases,accounting for 48％.CONCLUSION Anlotinib is used to treat esophageal malignant tumors,hepato-cellular carcinoma,and biliary tract cancer.It lacks high-quality evidence-based evidence and has limited benefits.It is recommended that clinical application of anlotinib should be comprehensively evaluated,and disease-related guide-lines and clinical evidence should be fully considered to ensure the safe and rational use of drugs.
AnlotinibEvidence-based evaluationRational drug use
万方数据
维普
